Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $169,639.94 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 1,819 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $93.26, for a total value of $169,639.94. Following the completion of the sale, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. The trade was a 10.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Blueprint Medicines Trading Down 4.9 %

NASDAQ BPMC opened at $91.78 on Thursday. The firm has a market cap of $5.83 billion, a PE ratio of -43.50 and a beta of 0.59. Blueprint Medicines Co. has a 52 week low of $72.24 and a 52 week high of $121.90. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The company has a 50 day moving average price of $92.41 and a 200 day moving average price of $97.29.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.97) by $0.08. Blueprint Medicines had a negative return on equity of 112.30% and a negative net margin of 29.48%. The firm had revenue of $128.20 million during the quarter, compared to analyst estimates of $127.56 million. During the same quarter in the prior year, the business posted ($2.20) EPS. The business’s revenue for the quarter was up 126.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Blueprint Medicines Co. will post -3.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on BPMC. JPMorgan Chase & Co. initiated coverage on Blueprint Medicines in a research note on Thursday, November 14th. They issued an “overweight” rating and a $126.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. Wells Fargo & Company lowered their price objective on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. JMP Securities reaffirmed a “market outperform” rating and set a $125.00 target price on shares of Blueprint Medicines in a research report on Monday, December 9th. Finally, Guggenheim reiterated a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, December 11th. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, Blueprint Medicines presently has an average rating of “Moderate Buy” and an average target price of $122.11.

Institutional Investors Weigh In On Blueprint Medicines

Several institutional investors have recently added to or reduced their stakes in the business. Exome Asset Management LLC purchased a new position in shares of Blueprint Medicines in the 3rd quarter valued at approximately $3,395,000. Franklin Resources Inc. increased its stake in Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock valued at $3,259,000 after purchasing an additional 265 shares in the last quarter. Synovus Financial Corp raised its holdings in shares of Blueprint Medicines by 4.0% in the third quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock worth $2,224,000 after buying an additional 922 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of Blueprint Medicines during the third quarter worth $202,000. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in shares of Blueprint Medicines by 23.7% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 16,520 shares of the biotechnology company’s stock worth $1,528,000 after buying an additional 3,162 shares during the period.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.